CDNA
CareDx Inc
NASDAQ: CDNA · HEALTHCARE · DIAGNOSTICS & RESEARCH
$79.81
-1.68% today
Updated 2026-11-12
Market cap
$4.59B
P/E ratio
36.88
P/S ratio
9.23x
EPS (TTM)
$2.37
Dividend yield
—
52W range
$14 – $91
Volume
1.4M
WallStSmart proprietary scores
60
out of 100
Grade: C+
Hold
Investment rating
8.7
Growth
A6.5
Quality
B5.5
Profitability
C+6.3
Valuation
B4/9
Piotroski F-Score
Moderate
0.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →259 stocks currently score above 75
Price targets
Analyst target
$82.00
+2.74%
12-Month target
—
—
Intrinsic (DCF)
$65.83
Margin of safety
+70.04%
0 Strong Buy5 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 25.90% — above average
+ Free cash flow $11.10M — positive
+ Revenue growth 39.30% QoQ
+ 70.04% below intrinsic value
+ Debt/equity 0.06x — low leverage
Risks
- Altman Z 0.36 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $321.79M | $280.32M | $333.79M | $379.81M | $497.40M |
| Net income | $-76.61M | $-190.28M | $52.55M | $-21.35M | $19.29M |
| EPS | — | — | — | — | $2.37 |
| Free cash flow | $-49.57M | $-27.63M | $31.56M | $36.12M | $11.10M |
| Profit margin | -23.81% | -67.88% | 15.74% | -5.62% | 25.90% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-06 | NOVACK, JEFFREY ADAM | Sale | 1,892 | $17.82 |
| 2026-04-02 | GOLDBERG, MICHAEL | Buy | 1,981 | — |
| 2026-04-01 | NOVACK, JEFFREY ADAM | Sale | 3,987 | $17.87 |
Peer comparison
Smart narrative
CareDx Inc trades at $79.81. representing a P/E of 36.88x trailing earnings. Our Smart Value Score of 60/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 0.36, it sits in the distress. TTM revenue stands at $497.40M. with profit margins at 25.90%. Our DCF model estimates intrinsic value at $65.83.
Frequently asked questions
What is CareDx Inc's stock price?
CareDx Inc (CDNA) trades at $79.81, on a P/E of 36.9x and a P/S of 9.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is CareDx Inc overvalued?
CareDx Inc carries a Smart Value Score of 60/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $65.83 versus the $79.81 price, a 70.0% margin of safety on a cash flow basis.
What is the price target of CareDx Inc (CDNA)?
The 12-month analyst consensus target is $82.00, about 2.7% above the current $79.81. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of CareDx Inc (CDNA)?
Our DCF model estimates intrinsic value at $65.83, a +70.0% margin of safety versus today's $79.81. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is CareDx Inc's revenue?
CareDx Inc's trailing twelve-month revenue is $497.40M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
CareDx Inc's Altman Z-Score is 0.36, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio9.23x
ROE-2.61%
Beta2.38
50D MA$59.93
200D MA$33.64
Shares out0.05B
Float0.05B
Short ratio—
Avg volume1.4M
Performance
1 week+39.69%
1 month+29.00%
3 months+12.04%
YTD+19.00%
1 year—
3 years—
5 years—